| 1 |
He XJ, Wang XL, Huang XY, Li DZ, Liu G, Wang W, Li DL. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial. Clin Res Hepatol Gastroenterol 2023;47:102052. [PMID: 36400418 DOI: 10.1016/j.clinre.2022.102052] [Reference Citation Analysis]
|
| 2 |
Zhao Z, Zou PY, Su NY, Guo Y, Wang XW, Zhao JT, Mei H, Shi Q, Wang B, Chen DF, Lan CH. High-dose dual therapy versus culture-based susceptibility-guided therapy as a rescue regimen for Helicobacter pylori infection: a randomized controlled trial. Therap Adv Gastroenterol 2022;15:17562848221145566. [PMID: 36600682 DOI: 10.1177/17562848221145566] [Reference Citation Analysis]
|
| 3 |
Zhou J, Shen Y, Song X, Zhou L, Tang H, Li H. Evaluation of a Molecular Mosprie Assay for Detection of Helicobacter pylori and Resistance to Clarithromycin and Levofloxacin. J Infect Dis 2022;226:S503-9. [PMID: 36478246 DOI: 10.1093/infdis/jiac402] [Reference Citation Analysis]
|
| 4 |
Qian HS, Li WJ, Dang YN, Li LR, Xu XB, Yuan L, Zhang WF, Yang Z, Gao X, Zhang M, Li X, Zhang GX. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy. Am J Gastroenterol 2022. [PMID: 36729890 DOI: 10.14309/ajg.0000000000002086] [Reference Citation Analysis]
|
| 5 |
Hu Y, Zhu Y, Lu NH. The management of Helicobacter pylori infection and prevention and control of gastric cancer in China. Front Cell Infect Microbiol 2022;12:1049279. [PMID: 36530421 DOI: 10.3389/fcimb.2022.1049279] [Reference Citation Analysis]
|
| 6 |
Han YY, Long H, Lin Y, He Q, Chen WG, Ding XW, Zhou L, An P, Wang F, Zhang ZY, Hu YL, Li PY. Optimized dual therapy for treatment-naive patients of Helicobacter pylori infection: A large-scale prospective, multicenter, open-label, randomized controlled study. Helicobacter 2022;27:e12922. [PMID: 35939559 DOI: 10.1111/hel.12922] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Jiang Z, Qian X, Wang Z, Dong Y, Pan Y, Zhang Z, Wang S. Antibiotic resistance of Helicobacter pylori isolated from patients in Nanjing, China: A cross-section study from 2018 to 2021. Front Cell Infect Microbiol 2022;12:970630. [DOI: 10.3389/fcimb.2022.970630] [Reference Citation Analysis]
|
| 8 |
Ouyang Y, Wang M, Xu YL, Zhu Y, Lu NH, Hu Y. Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis. J Gastroenterol Hepatol 2022;37:1666-72. [PMID: 35716370 DOI: 10.1111/jgh.15917] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 9 |
Hu Y, Xu X, Ouyang YB, He C, Li NS, Xie C, Peng C, Zhu ZH, Xie Y, Shu X, Lu NH, Zhu Y. Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study. Helicobacter 2022;27:e12896. [PMID: 35466521 DOI: 10.1111/hel.12896] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
Cho JH, Jin SY. Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea. World J Clin Cases 2022; 10(19): 6349-6359 [DOI: 10.12998/wjcc.v10.i19.6349] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 11 |
Zhang WL, Li YY, Liu J, Wang J, Wan M, Lin BS, Lin MJ, Ding YM, Kong QZ, Wang ST, Duan M, Han ZX, Ji R, Zuo XL, Li YQ. Clinical practice of Helicobacter pylori infection management by gastroenterologists in secondary and tertiary hospitals: A stratified sampling cross-sectional survey. J Dig Dis 2022;23:365-75. [PMID: 35880374 DOI: 10.1111/1751-2980.13119] [Reference Citation Analysis]
|
| 12 |
Buran T, Sürücüoğlu S, Kurutepe S, Gazi H. Recent trends in the antibiotic resistance of Helicobacter pylori in patient with dyspepsia. Medicine (Baltimore) 2022;101:e29801. [PMID: 35777028 DOI: 10.1097/MD.0000000000029801] [Reference Citation Analysis]
|
| 13 |
Zhang J, Rong C, Yan C, Chen J, Yang W, Yu L, Dai H. Risk factors of furazolidone-associated fever. PLoS ONE 2022;17:e0266763. [DOI: 10.1371/journal.pone.0266763] [Reference Citation Analysis]
|
| 14 |
Chen J, Huang Y, Ding Z, Liang X, Lu H. E-Test or Agar Dilution for Metronidazole Susceptibility Testing of Helicobacter pylori: Importance of the Prevalence of Metronidazole Resistance. Front Microbiol 2022;13:801537. [PMID: 35359733 DOI: 10.3389/fmicb.2022.801537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Shao QQ, Yu XC, Yu M, Ma J, Zhao JB, Yuan L, Qi YB, Hu RB, Wei PR, Xiao W, Lan L, Jia BL, Zhang LZ, Ding SZ. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial. Helicobacter 2022;27:e12876. [PMID: 35150597 DOI: 10.1111/hel.12876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 16 |
Li Y, Huang Z, Shang Y, Xie X, Yang R, Chen H, Wang Z, Xue L, Pang R, Zhang J, Ding Y, Chen M, Wang J, Chen J, Wu Q. Exploration of the molecular mechanisms underlying the antibiotic resistance of Helicobacter pylori: A whole-genome sequencing-based study in Southern China. Helicobacter 2022;27:e12879. [PMID: 35124867 DOI: 10.1111/hel.12879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 17 |
Ouyang Y, Zhang W, He C, Zhu Y, Lu N, Hu Y. Susceptibility-Guided Therapy vs. Bismuth-Containing Quadruple Therapy as the First-Line Treatment for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2022;9:844915. [PMID: 35402425 DOI: 10.3389/fmed.2022.844915] [Reference Citation Analysis]
|
| 18 |
Bai X, Zhu M, He Y, Wang T, Tian D, Shu J. The impacts of probiotics in eradication therapy of Helicobacter pylori. Arch Microbiol 2022;204:692. [PMID: 36344628 DOI: 10.1007/s00203-022-03314-w] [Reference Citation Analysis]
|
| 19 |
Wang J, Cao Y, He W, Li X. Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori. Medicine (Baltimore) 2021;100:e28323. [PMID: 34941132 DOI: 10.1097/MD.0000000000028323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Zhao Y, Yang Y, Aruna, Xiao J, Song J, Huang T, Li S, Kou J, Huang L, Ji D, Xiong S, Peng W, Xu S, Cheng B. Saccharomyces boulardii Combined With Quadruple Therapy for Helicobacter pylori Eradication Decreased the Duration and Severity of Diarrhea: A Multi-Center Prospective Randomized Controlled Trial. Front Med (Lausanne) 2021;8:776955. [PMID: 34869495 DOI: 10.3389/fmed.2021.776955] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 21 |
Huang Q, Jia X, Chu Y, Zhang X, Ye H. Helicobacter pylori Infection in Geriatric Patients: Current Situation and Treatment Regimens. Front Med (Lausanne) 2021;8:713908. [PMID: 34660627 DOI: 10.3389/fmed.2021.713908] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 22 |
Guo R, Wu S, Guan L, Xie Y, Yang X, Li Z, Zhang Z. Dietary multivalent anti-Helicobacter pylori immunoglobulin Y significantly increase the H. pylori eradication and improve the clinical symptoms in patients. Helicobacter 2021;26:e12843. [PMID: 34382297 DOI: 10.1111/hel.12843] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 23 |
Qiao C, Li Y, Liu J, Ji C, Qu J, Hu J, Ji R, Wan M, Lin B, Lin M, Qi Q, Zuo X, Li Y. Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area. J Gastroenterol Hepatol 2021;36:2383-8. [PMID: 33691344 DOI: 10.1111/jgh.15468] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 24 |
Li SY, Li J, Dong XH, Teng GG, Zhang W, Cheng H, Gao W, Dai Y, Zhang XH, Wang WH. The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing. Helicobacter 2021;26:e12804. [PMID: 33860967 DOI: 10.1111/hel.12804] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 25 |
Rokkas T, Gisbert JP, Malfertheiner P, Niv Y, Gasbarrini A, Leja M, Megraud F, O'Morain C, Graham DY. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology 2021;161:495-507.e4. [PMID: 33839101 DOI: 10.1053/j.gastro.2021.04.012] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 24.0] [Reference Citation Analysis]
|
| 26 |
Jin F, Yang H. Effects of Lactobacillus salivarius LN12 in Combination with Amoxicillin and Clarithromycin on Helicobacter pylori Biofilm In Vitro. Microorganisms 2021;9:1611. [PMID: 34442690 DOI: 10.3390/microorganisms9081611] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 27 |
Puah SM, Goh KL, Ng HK, Chua KH. Current status of Helicobacter pylori resistance to Clarithromycin and Levofloxacin in Malaysia-findings from a molecular based study. PeerJ 2021;9:e11518. [PMID: 34178444 DOI: 10.7717/peerj.11518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 28 |
Yang L, Zou A, Wu H, Guo H, Zhang F, Zou B, Wang J. Application of Visual Gene Clip-Based Tailored Therapy for the Eradication of Helicobacter pylori. Biomed Res Int 2021;2021:6150628. [PMID: 33937401 DOI: 10.1155/2021/6150628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 29 |
Brennan D, O’morain C, Mcnamara D, Smith SM. Molecular Detection of Antibiotic-Resistant Helicobacter pylori. In: Smith SM, editor. Helicobacter Pylori. New York: Springer US; 2021. pp. 29-36. [DOI: 10.1007/978-1-0716-1302-3_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 30 |
Zheng H, Xie Q, Zhan M, Jin C, Li Q. Cost‑effectiveness Analysis of Helicobacter pylori Eradication Therapy in First-Degree Relatives of Patients with Gastric Cancer. Patient Prefer Adherence 2021;15:77-85. [PMID: 33519193 DOI: 10.2147/PPA.S286860] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 31 |
Huang Q, Shi Z, Cheng H, Ye H, Zhang X. Efficacy and Safety of Modified Dual Therapy as the First-line Regimen for the Treatment of Helicobacter pylori Infection: A Meta-Analysis of Randomized Controlled Trials. J Clin Gastroenterol 2021;55:856-64. [PMID: 33074949 DOI: 10.1097/MCG.0000000000001448] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 32 |
Guo B, Cao NW, Zhou HY, Chu XJ, Li BZ. Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis. Microb Pathog 2021;152:104661. [PMID: 33249167 DOI: 10.1016/j.micpath.2020.104661] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 33 |
Chen Y, Liu Q, Hu F, Ma J. Identifying the best regimen for primary eradication of Helicobacter pylori: analysis of 240 cases. Microbiologyopen 2020;9:e1120. [PMID: 33026166 DOI: 10.1002/mbo3.1120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 34 |
Khiddi F, Abdellahi MVM, Horma MA, Billoet A, Collobert G, Amar AM, Nech HDM, Vadel EHM, Houmeida A, Raymond J, Dauga C, Gastli N. Characteristics of Helicobacter pylori strains isolated from Mauritanian patients. Helicobacter 2020;25:e12726. [PMID: 32686319 DOI: 10.1111/hel.12726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 35 |
Gao W, Ye H, Deng X, Wang C, Xu Y, Li Y, Zhang X, Cheng H. Rabeprazole-amoxicillin dual therapy as first-line treatment for H pylori eradication in special patients: A retrospective, real-life study. Helicobacter 2020;25:e12717. [PMID: 32548932 DOI: 10.1111/hel.12717] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 36 |
Tang X, Chen X, Shen Y, Yang T, Hu R, Debowski AW, Stubbs KA, Benghezal M, Marshall BJ, Li H, Tang H. Primary antibiotic resistance of Helicobacter pylori among a Chinese Tibetan population. Future Microbiol 2020;15:1353-61. [PMID: 32900223 DOI: 10.2217/fmb-2020-0206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 37 |
Yan TL, Gao JG, Wang JH, Chen D, Lu C, Xu CF. Current status of Helicobacter pylori eradication and risk factors for eradication failure. World J Gastroenterol 2020; 26(32): 4846-4856 [PMID: 32921961 DOI: 10.3748/wjg.v26.i32.4846] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 38 |
Azzaya D, Gantuya B, Oyuntsetseg K, Davaadorj D, Matsumoto T, Akada J, Yamaoka Y. High Antibiotic Resistance of Helicobacter pylori and Its Associated Novel Gene Mutations among the Mongolian Population. Microorganisms 2020;8:E1062. [PMID: 32708761 DOI: 10.3390/microorganisms8071062] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 39 |
Kasahun GG, Demoz GT, Desta DM. Primary Resistance Pattern of Helicobacter pylori to Antibiotics in Adult Population: A Systematic Review. Infect Drug Resist 2020;13:1567-73. [PMID: 32547126 DOI: 10.2147/IDR.S250200] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 40 |
Li RJ, Dai YY, Qin C, Li XH, Qin YC, Pan Y, Huang YY, Huang ZS, Huang YQ. Treatment strategies and preventive methods for drug-resistant Helicobacter pylori infection. World J Meta-Anal 2020; 8(2): 98-108 [DOI: 10.13105/wjma.v8.i2.98] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 41 |
Yang T, Hu R, Tang X, Shen Y, Tay A, Pi X, Wang G, Debowski AW, Stubbs KA, Benghezal M, Marshall BJ, Li H, Tang H. Susceptibility-guided bismuth quadruple therapies for resistant Helicobacter pylori infections. Precision Clinical Medicine 2020;3:127-35. [DOI: 10.1093/pcmedi/pbaa010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 42 |
Danilenko AA, Shakhtarina S, Falaleeva N. Primary Gastric Lymphomas. Клиническая онкогематология 2020;13:95-103. [DOI: 10.21320/2500-2139-2020-13-1-95-103] [Reference Citation Analysis]
|
| 43 |
Lee JY, Kim N, Nam RH, In Choi S, Lee JW, Lee DH. Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018. Helicobacter 2019;24:e12660. [PMID: 31507036 DOI: 10.1111/hel.12660] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 44 |
Safarov T, Kiran B, Bagirova M, Allahverdiyev AM, Abamor ES. An overview of nanotechnology-based treatment approaches against Helicobacter Pylori. Expert Review of Anti-infective Therapy 2019;17:829-40. [DOI: 10.1080/14787210.2019.1677464] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 45 |
Song C, Qian X, Zhu Y, Shu X, Song Y, Xiong Z, Ye J, Yu T, Ding L, Wang H, Lu N, Xie Y. Effectiveness and safety of furazolidone-containing quadruple regimens in patients with Helicobacter pylori infection in real-world practice. Helicobacter 2019;24:e12591. [PMID: 31111641 DOI: 10.1111/hel.12591] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 46 |
Choi YI, Jeong SH, Chung JW, Park DK, Kim KO, Kwon KA, Kim YJ, So S, Lee JH, Jeong JY, Lee SM. Rifabutin and Furazolidone Could Be the Candidates of the Rescue Regimen for Antibiotic-Resistant H. pylori in Korea. Can J Infect Dis Med Microbiol. 2019;2019:9351801. [PMID: 31360270 DOI: 10.1155/2019/9351801] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 47 |
Ko SW, Kim YJ, Chung WC, Lee SJ. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis. Helicobacter 2019;24:e12565. [PMID: 30698318 DOI: 10.1111/hel.12565] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 48 |
Gweon TG, Kim JS, Kim BW. An Economic Modeling Study of Helicobacter pylori Eradication: Comparison of Dual Priming Oligonucleotide-Based Multiplex Polymerase Chain Reaction and Empirical Treatment. Gut Liver 2018;12:648-54. [PMID: 30037167 DOI: 10.5009/gnl18079] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 49 |
Wang G, Pang J, Hu X, Nie T, Lu X, Li X, Wang X, Lu Y, Yang X, Jiang J, Li C, Xiong YQ, You X. Daphnetin: A Novel Anti-Helicobacter pylori Agent. Int J Mol Sci 2019;20:E850. [PMID: 30781382 DOI: 10.3390/ijms20040850] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 50 |
Smith SM, O'Morain C, McNamara D. Helicobacter pylori resistance to current therapies. Curr Opin Gastroenterol 2019;35:6-13. [PMID: 30489412 DOI: 10.1097/MOG.0000000000000497] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 51 |
Guo C, Liu F, Zhu L, Wu F, Cui G, Xiong Y, Wang Q, Yin L, Wang C, Wang H, Wu X, Zhang Z, Chen Z. Analysis of culturable microbiota present in the stomach of children with gastric symptoms. Braz J Microbiol 2019;50:107-15. [PMID: 30637659 DOI: 10.1007/s42770-018-0030-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 52 |
Song HY, Zhou L, Liu DY, Yao XJ, Li Y. What Roles Do Probiotics Play in the Eradication of Helicobacter pylori? Current Knowledge and Ongoing Research. Gastroenterol Res Pract 2018;2018:9379480. [PMID: 30410538 DOI: 10.1155/2018/9379480] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 53 |
O'Morain NR, Dore MP, O'Connor AJP, Gisbert JP, O'Morain CA. Treatment of Helicobacter pylori infection in 2018. Helicobacter 2018;23 Suppl 1:e12519. [PMID: 30203585 DOI: 10.1111/hel.12519] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 54 |
Xie Y, Zhu Z, Wang J, Zhang L, Zhang Z, Lu H, Zeng Z, Chen S, Liu D, Lv N; the Chinese Study Group on Helicobacter pylori, Chinese Society of Gastroenterology. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China. Antimicrob Agents Chemother 2018;62:e00432-18. [PMID: 29914954 DOI: 10.1128/AAC.00432-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 55 |
Flores-Treviño S, Mendoza-Olazarán S, Bocanegra-Ibarias P, Maldonado-Garza HJ, Garza-González E. Helicobacter pylori drug resistance: therapy changes and challenges. Expert Rev Gastroenterol Hepatol 2018;12:819-27. [PMID: 29976092 DOI: 10.1080/17474124.2018.1496017] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 56 |
Lopo I, Libânio D, Pita I, Dinis-Ribeiro M, Pimentel-Nunes P. Helicobacter pylori antibiotic resistance in Portugal: Systematic review and meta-analysis. Helicobacter 2018;23:e12493. [PMID: 29911329 DOI: 10.1111/hel.12493] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 57 |
Bachir M, Allem R, Benejat L, Tifrit A, Medjekane M, Drici AE, Megraud F, Douidi KT. Molecular detection of mutations involved in Helicobacter pylori antibiotic resistance in Algeria. Journal of Antimicrobial Chemotherapy 2018;73:2034-8. [DOI: 10.1093/jac/dky167] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 58 |
Zhuge L, Wang Y, Wu S, Zhao RL, Li Z, Xie Y. Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta-analysis. Helicobacter 2018;23:e12468. [PMID: 29480532 DOI: 10.1111/hel.12468] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 59 |
Xie Y, Pan X, Li Y, Wang H, Du Y, Xu J, Wang J, Zeng Z, Chen Y, Zhang G, Wu K, Liu D, Lv N. New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese prospective, randomized, multicentre trial. Journal of Antimicrobial Chemotherapy 2018;73:1681-7. [DOI: 10.1093/jac/dky056] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 60 |
Bachir M, Allem R, Tifrit A, Medjekane M, Drici AE, Diaf M, Douidi KT. Primary antibiotic resistance and its relationship with cagA and vacA genes in Helicobacter pylori isolates from Algerian patients. Braz J Microbiol. 2018;49:544-551. [PMID: 29452847 DOI: 10.1016/j.bjm.2017.11.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 61 |
Li H, Liang X, Chen Q, Zhang W, Lu H. Inappropriate treatment in Helicobacter pylori eradication failure: a retrospective study. Scand J Gastroenterol 2018;53:130-3. [PMID: 29214879 DOI: 10.1080/00365521.2017.1413132] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 62 |
Shao Y, Lu R, Yang Y, Xu Q, Wang B, Ye G. Antibiotic resistance of Helicobacter pylori to 16 antibiotics in clinical patients. J Clin Lab Anal. 2018;32:e22339. [PMID: 28984385 DOI: 10.1002/jcla.22339] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
|
